AiCure

Drug Sponsors

DPx to expand facility in North Carolina, add 488 jobs

Thursday, October 9, 2014 08:00 AM

DPx, the “umbrella name” for Patheon’s three business units specializing in pharmaceutical services, fine chemicals and proprietary products and technologies, will expand operations in Pitt County, N.C. The company plans to create 488 jobs in Greenville, N.C. by the end of 2019 and invest $159 million to increase the site’s capabilities, as well as modernize the site and develop energy efficiency programs at the facility.

More... »


Teva announces results of strategic review of core specialty therapeutic areas

Wednesday, October 8, 2014 01:49 PM

Teva Pharmaceutical Industries has identified 14 pipeline projects for discontinuation or divestment as part of its strategic review of core therapeutic areas for the company. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017.

More... »

CenterWatch

Allied Minds launches Novare Pharmaceuticals

Wednesday, October 8, 2014 01:47 PM

Allied Minds, a Boston, Mass.-based science and technology development and commercialization company, has launched Novare Pharmaceuticals, a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of Receptor for Hyaluronan Mediated Motility (RHAMM). Modulation of RHAMM also is of benefit in inflammatory diseases such as bronchopulmonary dysplasia (BPD).

More... »

Actavis to acquire Durata Therapeutics

Monday, October 6, 2014 04:00 PM

Actavis, a global specialty pharmaceutical company based in Dublin, Ireland, and Durata Therapeutics, an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, headquartered in Chicago, Ill., have entered into a definitive merger agreement.

More... »

FDA seeks permanent injunction against Pharmaceutical Innovations

Monday, October 6, 2014 03:46 PM

The FDA is seeking a permanent injunction to stop Pharmaceutical Innovations, and its principal officer, Gilbert Buchalter, from manufacturing, marketing, selling and distributing medical products until they come into compliance with all applicable FDA requirements.

More... »

Immutep to be acquired by Prima BioMed

Friday, October 3, 2014 11:04 AM

Immutep, an Orsay, France-based, late stage private biopharmaceutical company focused on immuno-oncology, has reached an agreement to be acquired by Prima BioMed, a Sydney, Australia-based developer of personalized immunocellular therapeutic products for cancer. Prima will pay up to approximately $28 million through a combination of cash, shares and warrants, subject to the achievement of certain performance milestones.

More... »

Salix Pharmaceuticals, Cosmo Technologies terminate merger agreement

Friday, October 3, 2014 10:50 AM

Salix Pharmaceuticals, based in Raleigh, N.C., and Lainate, Italy-based Cosmo Pharmaceuticals have agreed to terminate their previously-announced merger agreement pursuant to which Salix would have combined with, and become a wholly-owned subsidiary of, Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals. Effective immediately, Salix will make a $25 million payment to Cosmo.

More... »

BioNTech, Ganymed Pharmaceuticals open research headquarters in Germany

Thursday, October 2, 2014 02:14 PM

BioNTech and Ganymed Pharmaceuticals, two German biotechology companies, have opened a 108,000-square-foot headquarters and research facility. The new facility brings together 300 employees and is located near academic institutions, hospitals and cancer research institutions.

More... »

Baxter to form new innovation and R&D center for biopharmaceuticals

Wednesday, October 1, 2014 01:26 PM

Baxter International plans to form a new global innovation and R&D center in Cambridge, Mass., for Baxter's biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta in mid-2015.

More... »

Johnson & Johnson to acquire Alios BioPharma

Wednesday, October 1, 2014 01:04 PM

Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, a San Francisco-based, privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs